Working at the frontiers of remote patient monitoring and predictive analytics, Entia has combined novel at-home blood testing technology and digital solutions, to deliver personalised insights into cancer patients’ journeys through treatment.
Entia’s Series A financing round was led by BGF and Parkwalk, alongside the company’s other existing investors. The round is supporting the UK commercial roll-out and US regulatory approval of its flagship innovation, Liberty – the world’s most comprehensive remote patient monitoring solution for people undergoing cancer treatment.
The company’s solution is unique in being able to offer symptom and vitals tracking, alongside full blood count analysis that includes monitoring of neutropenia – one of the most common and costly side effects of cancer treatment. And we’re proud to be supporting the business with growth capital and support.
